查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024417

腫瘤分子診斷市場報告：按癌症類型、產品類型、技術、最終用戶和地區分類（2026-2034 年）

Oncology Molecular Diagnostics Market Report by Cancer Type, Product, Technology, End-User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球腫瘤分子診斷市場規模達53億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到151億美元，2026年至2034年的複合年成長率為11.87%。癌症發生率上升、分子診斷技術的不斷進步以及精準醫療的日益普及是推動市場成長的主要因素。

腫瘤分子診斷市場的發展趨勢：

人口老化

全球人口老化是推動市場成長的主要因素之一。例如，預計到2030年，全球每六個人中就有一人將年滿60歲或以上。屆時，60歲及以上人口的比例預計將從2020年的10億增加到14億。到2050年，全球60歲以上人口預計將翻倍（達到21億）。隨著老年人口的不斷成長，對高效能癌症診斷（尤其是基於分子檢測的診斷）的需求預計將會上升。這些因素預計將進一步積極影響腫瘤分子診斷市場的成長。

癌症發生率上升

全球癌症發生率持續上升，包括乳癌、肺癌、大腸癌和攝護腺癌在內的多種癌症病例在各個地區不斷增加。例如，世界衛生組織（WHO）的報導預測，到2050年，全球癌症病例將超過3,500萬例，比2022年估計的2,000萬例增加77%。同樣，美國國家癌症研究所2024年的報導指出，美國約有623,405人患有轉移性乳癌、前列腺癌、肺癌、結直腸癌、膀胱癌和黑色素瘤，預計到2025年，這一數字將增至約693,400人。這種激增推動了對更有效的早期癌症診斷工具的需求，使得分子診斷成為癌症治療的關鍵要素。這些因素表明，未來幾年腫瘤分子診斷的市場佔有率將會擴大。

技術進步

新一代定序（NGS）技術能夠快速定序整個基因組或特定基因組區域，從而提供關於癌症相關基因突變的詳細資訊。同時分析多個基因的能力徹底改變了癌症診斷，並實現了全面的腫瘤譜分析。例如，2024年10月，腫瘤診斷服務供應商NeoGenomics公司推出了AML Express，這是一種次世代定序（NGS）檢測方法，旨在為急性骨髓性白血病（AML）患者提供快速、全面的基因譜分析，從而擴大了腫瘤分子診斷市場的規模。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球腫瘤分子診斷市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依癌症類型分類

  • 乳癌
  • 攝護腺癌
  • 結腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 血癌
  • 其他

第7章 市場區隔：依產品分類

  • 裝置
  • 試劑
  • 其他

第8章 市場區隔：依技術分類

  • 聚合酵素鏈鎖反應（PCR）
  • 原位雜合反應
  • 晶片和微陣列
  • 恒溫核酸增幅技術（INAAT）
  • 質譜分析
  • DNA和NGS定序
  • 轉錄媒介增幅（TMA）
  • 其他

第9章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 測試機構
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Amadix
    • Cepheid
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc.
    • Illumina, Inc.
    • NeoGenomics Laboratories
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Veracyte Inc.
Product Code: SR112026A2396

The global oncology molecular diagnostics market size reached USD 5.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 15.1 Billion by 2034, exhibiting a growth rate (CAGR) of 11.87 % during 2026-2034. The rising prevalence of cancer, ongoing advancements in molecular diagnostic technologies, and increased adoption of precision medicine are primarily driving the market's growth.

ONCOLOGY MOLECULAR DIAGNOSTICS MARKET ANALYSIS:

  • Major Market Drivers: The rising prevalence of cancer on account of changing lifestyles, the growing geriatric population, and the increasing trend of smoking represent one of the major factors impelling the global oncology molecular diagnostics market growth. Apart from this, the escalating demand for rapid and accurate diagnosis, along with advancements in next-generation sequencing (NGS) techniques, is contributing to the oncology molecular diagnostics market share.
  • Key Market Trends: A rise in the number of individuals suffering from viral and bacterial infections and the increasing participation in blood donation campaigns is positively influencing the demand for oncology molecular diagnostics worldwide.
  • Competitive Landscape: Some of the prominent oncology molecular diagnostics market companies Abbott Laboratories, Amadix, Cepheid, F. Hoffmann-La Roche Ltd, Hologic, Inc., Illumina, Inc., NeoGenomics Laboratories, Qiagen N.V., Thermo Fisher Scientific Inc., and Veracyte Inc., among many others.
  • Geographical Trends: According to the oncology molecular diagnostics market dynamics, North America holds a prominent share of the oncology molecular diagnostics market, attributed to the high adoption of advanced diagnostic technologies and personalized medicine. Moreover, Europe is the second-largest region in the oncology molecular diagnostics market, driven by a robust regulatory framework and rising awareness about early cancer detection.
  • Challenges and Opportunities: The high cost of advanced diagnostics and the rising competition among key players are hampering the oncology molecular diagnostics market growth. However, with the global rise in cancer incidence, the demand for accurate and early diagnosis is increasing. Molecular diagnostics play a pivotal role in detecting cancer at early stages, leading to better outcomes and increased demand for diagnostic solutions.

ONCOLOGY MOLECULAR DIAGNOSTICS MARKET TRENDS:

Aging Population

The global aging population is one of the key factors driving the market's growth. For instance, by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population of persons aged 60 and up will double (2.1 billion). As the elderly population grows, the demand for effective cancer diagnostics, particularly those based on molecular testing, is expected to rise. These factors further positively influence the oncology molecular diagnostics market growth.

Rising Prevalence of Cancer

Cancer rates are rising globally, with an increasing number of cases of various cancers across various regions, such as breast, lung, colorectal, and prostate cancer. For instance, according to an article published by the World Health Organization (WHO), over 35 million more cancer cases are expected in 2050, up 77% over the estimated 20 million in 2022. Similarly, according to an article published by the National Cancer Institute in 2024, in the United States, there are nearly 623,405 persons living with metastatic breast, prostate, lung, colorectal, or bladder cancer , as well as metastatic melanoma, with that figure predicted to rise to approximately 693,400 by 2025. This surge is driving the demand for more effective diagnostic tools to detect cancer at earlier stages, making molecular diagnostics a critical component of cancer care. These factors are expected to propel the oncology molecular diagnostics market share in the coming years.

Technological Advancements

NGS technology enables the rapid sequencing of entire genomes or specific genomic regions, providing detailed insights into cancer-related genetic mutations. Its ability to analyze multiple genes simultaneously has revolutionized cancer diagnostics, allowing for the comprehensive profiling of tumors. For instance, in October 2024, NeoGenomics, Inc., a provider of oncology diagnostic services company, launched AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML), thereby boosting the oncology molecular diagnostics market size.

GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS INDUSTRY SEGMENTATION:

Breakup by Cancer Type:

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Others

According to the oncology molecular diagnostics market outlook, breast cancer remains one of the most common cancers globally, especially among women. The rising number of cases drives the demand for early detection tools and personalized treatment approaches. Moreover, the global rise in colorectal cancer cases, particularly in younger populations, is increasing the demand for early detection and prevention methods, where molecular diagnostics play a crucial role. Furthermore, the strong link between human papillomavirus (HPV) infection and cervical cancer has driven demand for molecular diagnostics that detect high-risk HPV strains (e.g., HPV-16, HPV-18), which are responsible for the majority of cervical cancer cases.

Breakup by Product:

  • Instruments
  • Reagents
  • Others

According to the oncology molecular diagnostics market overview, the increasing global burden of cancer is driving demand for molecular diagnostic instruments, which are essential for early detection, accurate diagnosis, and treatment monitoring. As more patients are diagnosed with cancer, the need for instruments like Next-Generation Sequencing (NGS) systems, PCR systems, and liquid biopsy platforms grows. Moreover, as more diagnostic tests are conducted globally due to the rising incidence of cancer, the need for reagents (e.g., enzymes, primers, probes, and assays) used in these tests is also increasing. Every diagnostic procedure-whether based on PCR, NGS, or immunohistochemistry (IHC)-requires consumable reagents, is driving the continuous demand.

Breakup by Technology:

  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization
  • Chips and Microarrays
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Mass Spectrometry
  • DNA and NGS Sequencing
  • Transcription Mediated Amplification (TMA)
  • Others

PCR is a well-established and widely used technology in oncology molecular diagnostics for detecting specific genetic mutations and viral oncogenes. It is used to identify common cancer-related mutations, such as KRAS, EGFR, and BRAF. Moreover, ISH techniques like Fluorescence in Situ Hybridization (FISH) are key to detecting gene amplifications (e.g., HER2 in breast cancer) and chromosomal translocations, essential in certain cancer diagnoses, such as lymphomas. Besides this, microarrays are widely used for gene expression profiling, enabling researchers and clinicians to assess the activity of thousands of genes simultaneously. This is particularly useful for understanding cancer biology and identifying prognostic biomarkers.

Breakup by End-User:

  • Hospitals and Clinics
  • Reference Laboratories
  • Others

The rising cancer incidence globally is pushing hospitals and clinics to adopt molecular diagnostic tools for early detection and diagnosis. Molecular diagnostics are particularly important in identifying cancer at earlier stages, where treatment is more likely to be effective. Moreover, reference laboratories handle a significant volume of oncology molecular diagnostics for multiple healthcare providers, including hospitals and clinics. They specialize in high throughput testing and advanced molecular diagnostics, creating a steady demand for technologies like NGS, PCR, and microarrays.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the oncology molecular diagnostics market statistics, North America, particularly the United States, has one of the highest rates of cancer, which drives the demand for molecular diagnostics for early detection, treatment selection, and monitoring. Moreover, many European countries have national cancer screening programs, particularly for breast, colorectal, and cervical cancers, increasing the adoption of molecular diagnostic tools. Besides this, the Asia-Pacific region is seeing a surge in cancer cases due to aging populations, lifestyle changes, and increasing urbanization. This rise is propelling the oncology molecular diagnostics market share.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Amadix
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • Veracyte Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global oncology molecular diagnostics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology molecular diagnostics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global oncology molecular diagnostics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Molecular Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cancer Type

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Prostate Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Colorectal Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cervical Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Liver Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Lung Cancer
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Blood Cancer
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Instruments
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Reagents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Polymerase Chain Reaction (PCR)
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 In Situ Hybridization
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Chips and Microarrays
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Mass Spectrometry
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 DNA and NGS Sequencing
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Transcription Mediated Amplification (TMA)
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Reference Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amadix
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Cepheid
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Hologic, Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Illumina, Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 NeoGenomics Laboratories
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Qiagen N.V.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Thermo Fisher Scientific Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Veracyte Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Oncology Molecular Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Molecular Diagnostics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Oncology Molecular Diagnostics Market: Breakup by Cancer Type (in %), 2025
  • Figure 4: Global: Oncology Molecular Diagnostics Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Oncology Molecular Diagnostics Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Oncology Molecular Diagnostics Market: Breakup by End-User (in %), 2025
  • Figure 7: Global: Oncology Molecular Diagnostics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Oncology Molecular Diagnostics (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Oncology Molecular Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Oncology Molecular Diagnostics (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Oncology Molecular Diagnostics (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Oncology Molecular Diagnostics (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Oncology Molecular Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Oncology Molecular Diagnostics (Cervical Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Oncology Molecular Diagnostics (Cervical Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Oncology Molecular Diagnostics (Liver Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Oncology Molecular Diagnostics (Liver Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Oncology Molecular Diagnostics (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Oncology Molecular Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Oncology Molecular Diagnostics (Blood Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Oncology Molecular Diagnostics (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Oncology Molecular Diagnostics (Other Cancer Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Oncology Molecular Diagnostics (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Oncology Molecular Diagnostics (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Oncology Molecular Diagnostics (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Oncology Molecular Diagnostics (Reagents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Oncology Molecular Diagnostics (Reagents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Oncology Molecular Diagnostics (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Oncology Molecular Diagnostics (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Oncology Molecular Diagnostics (Polymerase Chain Reaction-PCR) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Oncology Molecular Diagnostics (Polymerase Chain Reaction-PCR) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Oncology Molecular Diagnostics (In Situ Hybridization) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Oncology Molecular Diagnostics (In Situ Hybridization) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Oncology Molecular Diagnostics (Chips and Microarrays) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Oncology Molecular Diagnostics (Chips and Microarrays) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Oncology Molecular Diagnostics (Isothermal Nucleic Acid Amplification Technology-INAAT) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Oncology Molecular Diagnostics (Isothermal Nucleic Acid Amplification Technology-INAAT) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Oncology Molecular Diagnostics (Mass Spectrometry) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Oncology Molecular Diagnostics (Mass Spectrometry) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Oncology Molecular Diagnostics (DNA and NGS Sequencing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Oncology Molecular Diagnostics (DNA and NGS Sequencing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Oncology Molecular Diagnostics (Transcription Mediated Amplification-TMA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Oncology Molecular Diagnostics (Transcription Mediated Amplification-TMA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Oncology Molecular Diagnostics (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Oncology Molecular Diagnostics (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Oncology Molecular Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Global: Oncology Molecular Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Global: Oncology Molecular Diagnostics (Reference Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Global: Oncology Molecular Diagnostics (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Global: Oncology Molecular Diagnostics (Other End-Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Global: Oncology Molecular Diagnostics (Other End-Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: North America: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: North America: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: United States: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: United States: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Canada: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Canada: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Asia Pacific: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Asia Pacific: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: China: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: China: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Japan: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Japan: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: India: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: India: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: South Korea: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: South Korea: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Australia: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Australia: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Indonesia: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Indonesia: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Europe: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Europe: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Germany: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Germany: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: France: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: France: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: United Kingdom: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: United Kingdom: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Italy: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Italy: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Spain: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Spain: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Russia: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Russia: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Others: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Others: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Latin America: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Latin America: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Brazil: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Brazil: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Mexico: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 96: Mexico: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 97: Others: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 98: Others: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 99: Middle East and Africa: Oncology Molecular Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 100: Middle East and Africa: Oncology Molecular Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 101: Global: Oncology Molecular Diagnostics Industry: SWOT Analysis
  • Figure 102: Global: Oncology Molecular Diagnostics Industry: Value Chain Analysis
  • Figure 103: Global: Oncology Molecular Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oncology Molecular Diagnostics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Oncology Molecular Diagnostics Market Forecast: Breakup by Cancer Type (in Million USD), 2026-2034
  • Table 3: Global: Oncology Molecular Diagnostics Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 4: Global: Oncology Molecular Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Oncology Molecular Diagnostics Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 6: Global: Oncology Molecular Diagnostics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Oncology Molecular Diagnostics Market Structure
  • Table 8: Global: Oncology Molecular Diagnostics Market: Key Players